News

Carilion CEO Nancy Howell Agee to Retire

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1.

The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as a nurse in 1973. She was named Carilion’s president and CEO in 2011, becoming the health system’s seventh – and only female — top executive.

Agee earned national recognition for reorganizing Carilion as a fully integrated, physician-led clinic that includes a medical school and research institute with Virginia Tech, and served as chair of the American Hospital Association’s Board of Trustees in 2018.

She will serve as CEO emeritus through September 2025 and focus on philanthropy, growing Carilion’s partnerships and continuing to develop the health system’s reputation statewide and nationally.

Steve is a strong and capable leader whose commitment to our mission and deep knowledge of our entire organization make him well-suited for the CEO role,” said James Hartley, chairman of Carilion Clinic’s board of directors.

Arner has served as chief operating officer since 2012. He spearheaded more than $500 million in facilities investments, including the Crystal Spring Tower addition to Carilion Roanoke Memorial Hospital, on track for completion in 2025, and the recently opened Carilion Children’s and Mental Health facilities at Tanglewood. During the Covid-19 pandemic, he led the health system’s response, while also serving as chair of the Virginia Hospital and Healthcare Association.

“Carilion today is a nationally ranked academic health system that provides an extraordinary range of services, from primary care to the most advanced, complex care,” said Arner. “In some respects, it’s a far different organization than the one I joined more than 25 years ago. What has remained the same since the day I started is Carilion’s laser-like focus on its mission and our community, and I look forward to continuing on the path to growth and collaboration.”

Hartley added, “Carilion and our community have been the fortunate beneficiaries of Nancy’s talents for more than 50 years. I’m grateful to her for her continued service, and I’m grateful to Steve for advancing us to our next chapter.”

Read more here.

Recent News

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …